As of September 30, 2026, Vivani Medical, Inc. carries a market capitalization of 111.97M, placing it among publicly traded companies globally. Its enterprise value stands at 114.79M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 111.97M |
| Enterprise Value | 114.79M |
Vivani Medical, Inc.'s next confirmed earnings release is scheduled for April 1, 2027.
| Earnings Date | 4/1/2027 |
As of September 30, 2026, Vivani Medical, Inc. has 90.30M shares outstanding.
| Shares Outstanding | 90.30M |
These figures are as of September 30, 2026.
| PB Ratio | 8.47 |
| P/TBV Ratio | 8.47 |
| P/FCF Ratio | -4.00 |
| P/OCF Ratio | -4.06 |
As of September 30, 2026, Vivani Medical, Inc. maintains a current ratio of 2.40, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.40 |
| Quick Ratio | 2.26 |
| Debt / Equity | 131.73 |
| Debt / EBITDA | -0.63 |
Over the twelve months ended September 30, 2026, Vivani Medical, Inc. posted a negative return on equity (ROE) of -372.18, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -89.58, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 42.00, a quick read on workforce productivity versus industry peers.
| Return on Equity (ROE) | -372.18 |
| Return on Assets (ROA) | -89.58 |
| Employee Count | 42.00 |
As of the close on November 16, 2026, Vivani Medical, Inc.'s stock has declined approximately 28.17% over the past 52 weeks. The 50-day moving average sits at 1.17, while the 200-day moving average is 1.24.
| 52-Week Price Change | -28.17% |
| 50-Day Moving Average | 1.17 |
| 200-Day Moving Average | 1.24 |
Over the twelve months ended September 30, 2026, Vivani Medical, Inc. generated - - in revenue and converted that into -27.03M in net income, yielding earnings per share of -0.33. EBITDA reached -27.53M, while operating income came in at -28.03M.
| Operating Income | -28.03M |
| Pretax Income | -27.03M |
| Net Income | -27.03M |
| EBITDA | -27.53M |
| EBIT | -28.03M |
| Earnings Per Share (EPS) | -0.33 |
As of September 30, 2026, Vivani Medical, Inc. holds 14.59M in cash and equivalents against 17.41M in total debt, resulting in a net debt position of -14.59M. Total book value stands at 13.22M, with working capital of 9.25M providing operational flexibility.
| Cash & Cash Equivalents | 14.59M |
| Total Debt | 17.41M |
| Net Debt | -14.59M |
| Equity (Book Value) | 13.22M |
| Book Value Per Share | 0.15 |
| Working Capital | 9.25M |
Vivani Medical, Inc. produced -25.34M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -376,000.00 in capital expenditures, free cash flow totaled -25.72M - equivalent to -0.31 per share.
| Operating Cash Flow | -25.34M |
| Capital Expenditures | -376,000.00 |
| Free Cash Flow | -25.72M |
| FCF Per Share | -0.31 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -24.99: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -33.24, meaning Vivani Medical, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -33.24 |
| FCF Yield | -24.99 |
Vivani Medical, Inc.'s most recent stock split took place on August 19, 2022 with a 3:1 split ratio.
| Last Split Date | 8/19/2022 |
| Split Ratio | 3:1 |
As of September 30, 2026, Vivani Medical, Inc. has an Altman Z-Score of -5.96, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -5.96 |